Gothenburg – – September 10, 2026 -- Epicyt Pharma AB reported positive topline results from a Phase 1/2a first-in-human study of its oral drug candidate BAFA, showing a statistically significant reduction in urinary calcium excretion in patients who underwent Roux-en-Y gastric bypass (RYGB) surgery. The Gothenburg-based clinical-stage biopharmaceutical company said the trial, completed in March 2026, also recorded improvements in key biomarkers of calcium homeostasis, consistent with enhanced intestinal calcium uptake.

Los Angeles – September 10, 2026 -- Schall, Brown & Schwartz LLP (SBS) has issued a reminder to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a securities class action lawsuit alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The lead plaintiff deadline is set for September 28, 2026.

Los Angeles -- Shareholders of Pentair plc (NYSE: PNR) have until October 2, 2026 to seek lead plaintiff status in a securities fraud class action filed against the water treatment and pool equipment manufacturer, according to Schall, Brown & Schwartz LLP (SBS).

Los Angeles – September 10, 2026 -- Schall, Brown & Schwartz LLP has filed a class action lawsuit against Blaize Holdings, Inc. (NASDAQ: BZAI), alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The lawsuit covers investors who purchased BZAI shares between July 18, 2025 and April 28, 2026, with a lead plaintiff filing deadline set for October 5, 2026.

Los Angeles – September 10, 2026 -- DJS Law Group has reminded shareholders of a class action lawsuit filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The suit covers investors who purchased BBNX shares between July 30, 2025 and February 24, 2026, with a lead plaintiff filing deadline set for November 3, 2026.

Los Angeles – – September 10, 2026 -- Schall, Brown & Schwartz LLP has filed a federal securities class action against Beta Bionics, Inc. (NASDAQ: BBNX), alleging the company misled investors about FDA findings tied to its iLet Bionic Pancreas insulin pump. The case, Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999, is pending in the U.S. District Court for the Central District of California.

New York – September 10, 2026 -- Gaming peripherals brand ATTACK SHARK has struck a partnership with Cloud9 Esports, one of North America's most decorated e-sports organizations, to equip its League of Legends roster with hardware for daily training and competition prep.

Los Angeles – September 10, 2026 -- DJS Law Group has issued a reminder to investors of a securities class action lawsuit against GPGI, Inc., formerly known as CompoSecure, Inc. (NYSE: GPGI), with a lead plaintiff deadline set for September 15, 2026.

San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has filed a securities class action against Regeneron Pharmaceuticals (NASDAQ: REGN) after the failure of a Phase 3 melanoma trial wiped out $11 billion in market capitalization. The suit covers investors who purchased Regeneron shares between August 1, 2025, and May 15, 2026, with a lead plaintiff deadline set for September 14, 2026.

San Francisco – September 10, 2026 -- A securities class action has been filed against PROCEPT BioRobotics Corporation (NASDAQ: PRCT), alleging the company inflated handpiece sales through an undisclosed bulk-discount program that pulled forward demand and masked deteriorating customer inventory levels. Law firm Hagens Berman Sobol Shapiro LLP is representing investors who purchased PROCEPT stock between February 28, 2024 and February 25, 2026, with a lead plaintiff deadline set for September 22, 2026.